HER2 Testing in Breast Cancer: Clinical Relevance, Need, Testing Methods, Guidelines, and Interpretation of Results (Part 2)

Join Drs. Yuan and Callahan as they continue their discussion on HER2+ testing by reviewing our current understanding of HER2+ low and how it differs from HER2+ and HER2 negative. They explore the role of neoadjuvant therapy in HER2+ patients, post-operative phenotype shifts, and the need for HER2+ testing after surgery. They share cases from their practices where these issues arose and discuss how clinicians should approach post-treatment testing, including the concept of microtumor residual disease. Additionally, they examine precision medicine's role in improved HER2+ testing, including the potential of AI to enhance testing accuracy. Finally, they discuss the distinctions between HER2 low and HER2 ultralow.